{
    "organizations": [],
    "uuid": "aae9e1d72283868119acce10c4c5fdd409deb4eb",
    "author": "",
    "url": "https://www.reuters.com/article/brief-lilly-and-sigilon-therapeutics-ann/brief-lilly-and-sigilon-therapeutics-announce-strategic-collaboration-to-develop-encapsulated-cell-therapies-idUSFWN1RH04N",
    "ord_in_thread": 0,
    "title": "BRIEF-Lilly And Sigilon Therapeutics Announce Strategic Collaboration To Develop Encapsulated Cell Therapies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4, 2018 / 11:12 AM / in 13 minutes BRIEF-Lilly And Sigilon Therapeutics Announce Strategic Collaboration To Develop Encapsulated Cell Therapies Reuters Staff 2 Min Read \nApril 4 (Reuters) - Eli Lilly and Co: \n* LILLY AND SIGILON THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP ENCAPSULATED CELL THERAPIES FOR THE TREATMENT OF TYPE 1 DIABETES \n* SIGILON TO RECEIVE UPFRONT PAYMENT OF $63 MILLION AND UNDISCLOSED EQUITY INVESTMENT \n* PRODUCING CELLS FOR POTENTIAL TREATMENT OF TYPE 1 DIABETES \n* LILLY WILL RECEIVE AN EXCLUSIVE WORLDWIDE LICENSE TO SIGILON’S AFIBROMER TECHNOLOGY FOR ISLET CELL ENCAPSULATION \n* SIGILON IS ALSO ELIGIBLE TO RECEIVE UP TO $410 MILLION IN DEVELOPMENT AND COMMERCIALIZATION MILESTONES \n* PROCESS RESEARCH AND DEVELOPMENT CHARGE TO EARNINGS OF APPROXIMATELY $0.05 PER SHARE IN Q2 OF 2018 \n* ‍AFTER IND IS SUBMITTED,CO WILL BE RESPONSIBLE FOR ALL CLINICAL DEVELOPMENT & COMMERCIALIZATION ACTIVITIES & COSTS RELATED TO COLLABORATION​ \n* GAAP EARNINGS PER SHARE GUIDANCE AS A RESULT OF THE TRANSACTION \n* ‍SIGILON WILL BE RESPONSIBLE FOR ALL DEVELOPMENT ACTIVITIES & COSTS RELATED TO COLLABORATION UNTIL SUBMISSION OF IND \n* SIGILON ELIGIBLE TO GET SINGLE TO DOUBLE DIGIT TIERED ROYALTIES ON FUTURE PRODUCT SALES IF DEAL YIELDS COMMERCIALLY SUCCESSFUL PRODUCT Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)",
    "published": "2018-04-04T14:11:00.000+03:00",
    "crawled": "2018-04-04T14:28:03.023+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "minute",
        "sigilon",
        "therapeutic",
        "announce",
        "strategic",
        "collaboration",
        "develop",
        "encapsulated",
        "cell",
        "therapy",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "eli",
        "lilly",
        "co",
        "lilly",
        "sigilon",
        "therapeutic",
        "announce",
        "strategic",
        "collaboration",
        "develop",
        "encapsulated",
        "cell",
        "therapy",
        "treatment",
        "type",
        "diabetes",
        "sigilon",
        "receive",
        "upfront",
        "payment",
        "million",
        "undisclosed",
        "equity",
        "investment",
        "producing",
        "cell",
        "potential",
        "treatment",
        "type",
        "diabetes",
        "lilly",
        "receive",
        "exclusive",
        "worldwide",
        "license",
        "sigilon",
        "afibromer",
        "technology",
        "islet",
        "cell",
        "encapsulation",
        "sigilon",
        "also",
        "eligible",
        "receive",
        "million",
        "development",
        "commercialization",
        "milestone",
        "process",
        "research",
        "development",
        "charge",
        "earnings",
        "approximately",
        "per",
        "share",
        "q2",
        "ind",
        "submitted",
        "co",
        "responsible",
        "clinical",
        "development",
        "commercialization",
        "activity",
        "cost",
        "related",
        "gaap",
        "earnings",
        "per",
        "share",
        "guidance",
        "result",
        "transaction",
        "responsible",
        "development",
        "activity",
        "cost",
        "related",
        "collaboration",
        "submission",
        "ind",
        "sigilon",
        "eligible",
        "get",
        "single",
        "double",
        "digit",
        "tiered",
        "royalty",
        "future",
        "product",
        "sale",
        "deal",
        "yield",
        "commercially",
        "successful",
        "product",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}